MDC Translational Science and Clinical Research Grants Competition Opens for 2024-25
Muscular Dystrophy Canada’s annual Neuromuscular Research Grant Program is now open for 2024-25!
The annual Neuromuscular Research Grant Program invests in projects related to the diagnosis, treatment, or clinical care of neuromuscular disorders. These grants are intended to: fill gaps in the existing funding landscape; enable researchers to build new and innovative research; support proof-of-concept, feasibility and pilot studies in preparation for larger-scale, longer-term grants from external sources. MDC grants also facilitate partnerships between researchers and patients.
Two streams are available: Translational Science Grants and Clinical Research Grants
- Application Open: September 3, 2024
- Application Deadline: November 18, 2024 at 11:59 pm (ET)
- Notice of Decision: March 3, 2025
- Funding Start Date: April 1, 2025
MDC welcome research grants focused on one or multiple neuromuscular disorders (NMD). In this cycle, we especially encourage proposals focusing on Friedreich ataxia, Charcot-Marie-Tooth disease / hereditary motor and sensory neuropathies (HMSN), myotonic dystrophy, limb-girdle muscular dystrophy and collagen VI-related dystrophy.
Visit the MDC Translational Science and Clinical Research Grants webpage to learn more, or view the funding application guidelines here. For further inquiries, please contact Dr. Homira Osman, VP of Research and Public Policy, Muscular Dystrophy Canada at .
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.